{"id":"W2597083162","doi":"10.1182/blood.v128.22.1849.1849","title":"A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Rituximab; Tolerability; Medicine; Diffuse large B-cell lymphoma; Internal medicine; Phases of clinical research; Lymphoma; Ibrutinib; Refractory (planetary science); Pharmacology; Adverse effect; Oncology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002009863,0.002419638,0.002238828,0.0007772897,0.0006939172,0.001420865,0.001433993,0.0016157,0.00367781],"category_scores_gemma":[0.0008165972,0.0009097591,0.001162784,0.0005745433,0.001339632,0.001298212,0.0004420834,0.004619692,0.001168518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001261421,"about_ca_system_score_gemma":0.002118998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001389128,"about_ca_topic_score_gemma":0.003093065,"domain_scores_codex":[0.9994085,0.0002266861,0.00002607406,0.0001307508,0.00008351166,0.0001244804],"domain_scores_gemma":[0.9991117,0.00009680794,0.0001169957,0.0001001218,0.00008168435,0.0004926774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4021482,0.3854316,0.003734923,0.0008433818,0.00138449,0.0002894415,0.0004298495,0.003996554,0.1279775,0.0004515465,0.00497148,0.06834091],"study_design_scores_gemma":[0.3757527,0.6081529,0.00514395,0.0000207343,0.0002852445,0.0002185023,0.00007200906,0.001639524,0.006553538,0.0001950094,0.001923522,0.00004229458],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917368,0.001008923,0.0008396956,0.0003492859,0.0001406745,0.003665474,0.0009150144,0.0001359176,0.001208193],"genre_scores_gemma":[0.9850646,0.00123122,0.003123075,0.0007690599,0.0001925494,0.004073098,0.002252927,0.00005165601,0.00324179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00367781,"threshold_uncertainty_score":0.01230353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06246897875367131,"score_gpt":0.3669949671782259,"score_spread":0.3045259884245546,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}